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Abstract Not much  is known about the side eVects of
mitomycin C (MMC), an anti-Wbrogenetic agent, in the
upper aerodigestive tract. However, its use in ophthalmol-
ogy is widely known and without quantitatively important
side eVects. A literature review was performed for side
eVects of MMC in the upper aerodigestive tract. Forty-six
articles, describing the use of MMC to prevent scarring,
were retracted from PubMed. Thirty-two are human stud-
ies. MMC is used in diVerent concentrations (0.1–10 mg/
ml) with diVerent application times (2–5 min) and frequen-
cies (up to 4 times). Five hundred and thirty-eight patients
were included in those publications, of whom 19 developed
side eVects (3.53%). No side eVects developed in studies,
where post-application irrigation with saline was reported.
The longest mean follow-up period is 75.5 months. Direct
relations between the reported side eVects and MMC seem
absent in most studies. Serious complications seem to occur
when MMC is used in high concentrations. Unfortunately,
sometimes crucial information is lacking. One patient was
described who supposedly developed laryngeal carcinoma
after repeated treatment of hyperkeratosis and anterior
commissure webbing. Animal studies show that excessive
Wbrin production can lead to acute airway obstruction. In
conclusion, topical application of MMC on a wound with
consecutive irrigation with saline can be performed safely
to prevent scar formation in circular structures of the upper
aerodigestive tract. Long-term yearly control of the applica-
tion site seems advisable.
Keywords Mitomycin C · Administration, topical · Side 
eVects · Otorhinolaryngology · Upper aerodigestive tract
Introduction
Surgery inevitably leads to scarring. Surgery in circular
structures can lead to circumferential scarring. A circumfer-
ential scar with the formation of Wbrotic tissue is bound to
induce complications. Mitomycin C (MMC) is known and
widely used as a chemotherapeutic agent. More recently, its
use was realized as an application following surgery to pre-
vent scarring in circular structures in ophthalmology and
otorhinolaryngology. Not much is known about the side
eVects of MMC.
The Wrst article about using MMC to reduce living cells
in vitro dates from 1968 [1]. It is an antibiotic isolated from
the Streptomyces caespitosus. MMC operates by disrupting
base paring of DNA molecules in the G-1 phase. The G-1
phase is the Wrst stage of the cell cycle where the amount of
cytoplasm and proteins increases in preparation of the
fourth stage: mitosis. By this disrupting action, it inhibits
the formation of RNA and protein synthesis and in this way
inhibits the proliferation of Wbroblasts [1].
An additional function is the induction of apoptosis in
the Wbroblasts [2, 3]. Furthermore, MMC blocks angiogen-
esis [4]. Because of the induction of apoptosis MMC can be
toxic when given as systemic treatment. As topical therapy,
however, it can be of good help, as it seems not to induce
systemic toxicity.
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In recent literature and clinical practice, there is still no
consensus whether it is safe or not to use MMC, concerning
the (long term) side eVects. In addition, a standard for the
dosage seems to be lacking. There is research to the optimal
dose–eVect relation, but still there are conXicts of results
[5].
In ophthalmology, the use of MMC has proved to posi-
tively contribute treatment regimes. In ocular and lacrimal
duct surgery, MMC is known as a chemostatic agent [6, 7].
However, it is not free of local side eVects. Khong and
Muecke stated that 34% of the population developed an
allergic reaction, and 14% of their patients developed
epiphora as a result of punctal stenosis [6]. One patient
developed ptosis as a result of eye-lid edema. Despite these
side eVects, Khong and Muecke state that MMC is safe to
use and that no serious complications were observed [6].
Currently, MMC is more and more used as an anti-
Wbrotic agent [8, 9]. In a randomized clinical trial (RCT),
Tabatabaie et al. used MMC after treatment of nasolacrimal
duct obstruction. They found a signiWcantly better result
using MMC in comparison with a saline solution intraoper-
atively [8]. Only one of 88 patients developed a granuloma
near the punctum of the lacrimal duct. Yildirim et al. in
their RCT, found no beneWcial eVect of MMC after external
dacryocystorhinostomy (EXT-DCR). One of 20 eyes in the
MMC group developed epiphora, which was not signiW-
cantly less compared with the control group [9].
In the upper aerodigestive tract, MMC is mostly used
for the prevention of scarring. Consequently, this will
lead to a diVerent appreciation of side eVects. Because
MMC is more and more used as an anti-Wbrogenetic agent
in adults as well in children, it is important to present a
clear view on any reported side eVects and to report about
its safety. The purpose of this study is to Wnd out whether
it is safe enough to use MMC topically in the upper aero-
digestive tract.
Materials and methods
A search for articles about the use of MMC in the aerodi-
gestive tract was performed in Pubmed. The search was
until October 2008. The following meSH headings were
used: mitomycin along with choanal atresia, glottis, larynx,
nose, (o)esofagus, pharynx, stenosis or trachea.
For inclusion of studies, the following criteria were
used:
• The use of MMC to prevent scar formation and/or steno-
sis in animals and humans after intervention in the aero-
digestive tract.
• Study design had to be randomized or prospective clini-
cal trial, case series, case reports or review.
Results
Forty-six articles could be used. These 46 consisted of 11
case reports [10–20], 9 case series [21–29], 7 prospective
clinical trials [3, 30–35], 5 RCTs [36–40], 2 reviews [41,
42], 12 animal studies [4, 5, 43–52]. The Wrst article about
the topical use of MMC in the upper aerodigestive tract
dates from 1998 [19]. The meSH heading “(o)esofagus”
provided articles that were not contributing in the context
of our study, as almost all dealt with the use of MMC as a
chemotherapeutic agent for cancer.
Of the 46 selected articles, 32 are used for human popu-
lation with a total number of 538 patients. Of these patients,
257 are males and 165 are females, while the gender of the
remaining 116 patients is not mentioned. Of 490 patients,
the age has been recorded: 137 are children (<16 years) and
353 are adults. The mean age was 34.8 years. A summary
of the articles with the patient characteristics is shown in
Table 1.
All 32 human studies used MMC topically. DiVerent
concentrations were used, ranging from 0.1 to 10 mg/ml
(median 0.4, modus 0.4). The number of applications
diVers from 1 in most studies up to 12 times in one study
(mean 1.17, median 1, modus 1).
Twenty-eight of 32 human studies mentioned applica-
tion times of MMC. It ranged from 2 to 5 min. The mean
application time of all patients was 4.06 min (median
4 min, modus 4 and 5 min). Twenty-seven out of 28 studies
reported the use of cottonoid pledges or non-woven neuro-
patties soaked in an MMC solution were used. The last
group sprinkled MMC at the operation site [35]. Eight of 28
studies reported that the operation site was irrigated with an
isotonic saline solution, after the use of MMC.
The average follow-up period (which was reported in 27
of 32 studies) was 14.5 months, with a median of
18 months.
Nineteen of the 538 patients developed symptoms of
local side eVects. These studies are described in the section
below. Not any of the side eVects was reported in the stud-
ies where the wound was irrigated with a saline solution
afterwards. No systemic side eVects were reported
(Table 1). Studies in which no side eVects were reported
will not be discussed in this paper.
Fourteen of all 46 studies that were researched are ani-
mal studies (n = 12) or reviews (n = 2). Four of the animal
studies report side eVects, and these studies will also be
clariWed and discussed.
Side eVects in human studies
Local side eVects diVer depending on the anatomic area of
MMC has been applied. They will, therefore, be reported in
anatomical sequence.Eur Arch Otorhinolaryngol (2010) 267:327–334 329
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Anand et al. [36] performed an RCT in which they
applied MMC at one side after bilateral ethmoidectomy and
maxillary antrostomy. Nine of 29 patients experienced ste-
nosis or synechia formation. Seven of 12 episodes of
unwanted sequelae occurred on the MMC treated side.
There was no statistically signiWcant diVerence between the
Table 1 MMC in the aerodigestive tract in human studies: study design, patient characteristics, application details, follow-up and side eVects
MMC mitomycin C, RCT randomized clinical trial, a adult, c child, a/c the MMC was used on adults and children but exact data is lacking, y yes,
n no, none no reported side eVects
References Design n Mean patient 
age at start 
MMC (years)
Application 
dose 
(mg/mL)
MMC 
application 
time (min)
Number of 
applications
Saline 
irrigation 
(y/n)
Follow-up 
period 
(months)
Side 
eVects/
complications
Afzal [10] Case report 1 1.5 0.1 2 2 n 18 None
Agrawal [11] Case report 1 57 0.4 Not reported 1 n 36 Squamous cell 
carcinoma
Anand [36] RCT 29 49 0.5 5 1 n 15 Synechia/
stenosis
Chan [37] RCT 45 49 0.5 5 1 n 6 None
Chung [38] RCT 55 44.5 0.4 4 1 y 4.1 None
Dolmetsch [21] Case series 60 5.6 0.5 5 1 n 12.3 None
Gupta [30]P r o s p e c t i v e  
clinical trial
30 30 0.4 4 1 y Not reported None
Hartnick [39] RCT 11 3.6 0.2 2 1 n Not reported None
Hueman [22] Case series 44 44.8 0.4–10 4 1–4 n Not reported Partial airway 
obstruction
Isa [23] Case series 4 40.5 0.4 4 1 y 31 None
Konstantinidis [40] RCT 30 29.5 0.5 5 2 y 7.2 None
Kim [31]P r o s p e c t i v e  
clinical trial
20 31 0.4 5 1 n 13.3 None
Koshkareva [24] Case series 15 54 0.4 Not reported 1 n Not reported None
Kubba [25] Case series 22 <1 2 2 1 n 7 None
Mathiasen [12] Case report 1 3.5 0.4 4 1 n 12 None
Monnier [13] Case report 4 1 2 2 1 n 24 None
Monoo-KuoW [26] Case series 28 51.7 0.6 5 1–3 n 22 None
Nouraei [27] Case series 31 47 1 3 1 n 14.6 Reduced 
free interval
PenaWel [14] Case report 1 Not reported 0.5 2 1 n 24 None
Perepelitsyn [28] Case series 16 Not reported 0.4 4 1–3 y 4 None
Phillips [15] Case report 1 18 2 4 2 n 12 None
Rahbar [3]P r o s p e c t i v e  
clinical trial
15 5.7 0.4 4 1 y 18 None
Rahbar [32]P r o s p e c t i v e  
clinical trial
14 34 0.4 4 1–3 y 18 None
Roh [16] Case report 1 45 0.4 5 1 n 24 None
Roh [33]P r o s p e c t i v e  
clinical trial
14 57.7 0.4 5 1 n Not reported Glottic web
Roh [34]P r o s p e c t i v e  
clinical trial
17 41 0.4 5 1 y 18 None
Rosseneu [35]P r o s p e c t i v e
clinical trial
16 4 0.1 3.5 1–12 n 60 None
Salvado [17] Case report 1 68 0.4 4 1 n 15 None
Unal [18] Case report 1 0.8 1 5 1 n 4 None
Valdez [29] Case series 6 50 Not reported Not reported 1–2 n 75.5 None
Ward [19] Case report 3 7.5 0.1 2 1 n 24 None
Zur [20] Case report 1 15 1 Not reported 2 n 33 None
Total 538330 Eur Arch Otorhinolaryngol (2010) 267:327–334
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user and the non-user group. There were no major compli-
cations in this cohort of patients.
Hueman and Simpson treated 44 patients suVering from
laryngotracheal stenosis with MMC in two diVerent doses
[22]. Eighty-Wve procedures with MMC were performed. A
supersaturated dose of MMC (10 mg/ml) was used when a
low-dose solution of MMC (0.4 mg/ml) was not eVective
after applying up to four times. The high-dose MMC was
used in 14/85 procedures. Four patients developed compli-
cations due to severe local reaction: two children, in whom
the high concentration of MMC was used, and two adults
where the low-dose MMC was applied. All four patients
suVered from respiratory distress, as a result of edema and
debris. In one of the two children, this eventually led to expi-
ration. The patient was known with glottic stenosis and
recurrent respiratory papillomatosis that was treated with
laser removal and cidofovir, followed by scar dilatation and
the use of MMC. After 2 days, the child developed dyspnoea
and eventually experienced a respiratory arrest. He expired
10 days later, due to local consequences in the larynx (debris
and inXammation). However, in this case series, there was
no signiWcantly higher rate of complications in the high-dose
group (2 of 14 procedures) in comparison with the low-dose
group (2 of 71 procedures). Hueman and Simpson state that
this can be a result of the small number of patients.
In a non-controlled, non-randomized study, Roh and
Yoon looked for the outcome after the treatment for ante-
rior commissure carcinomas (microsurgery with immediate
MMC application 0.4 mg/ml for 5 min) [33]. In 5 of 15
patients, an acceptably small web was formed. The webs
did not have an inXuence on the vocal quality. One anterior
glottic stenosis needed lysis and additional use of MMC.
Eventually, no signiWcant local side eVects resulted from
the MMC and no vocal fold atrophy was found in the
patients with limited microsurgery [33].
Agrawal and Morrison wrote a case report about a 57-
year-old non-smoking and non-drinking male with a long
history of chronic laryngitis with the removal of a polyp and
keratosis (left vocal fold) [11]. Laryngoscopy showed a web
at the anterior commissure. This was treated with microlar-
yngoscopy, laser and application of topical MMC 0.4 mg/
ml. During follow-up, the patient developed a granuloma
and a new anterior web occurred. This was also treated with
laser. After 2.5 years, a T1aN0M0 squamous cell carcinoma
on the right vocal fold developed. The carcinoma was
locally resected and subsequent radiotherapy followed [11].
Nouraei et al. did a study towards the optimal treatment
of post-intubation airway stenosis [27]. They compared a
group of 11 patients with fresh lesions and stenoses with a
group of 20 patients with mature stenoses. The Wrst group
was treated with intralesional steroids, laser, reduction in
granulation tissue and balloon dilatation. The second group
was treated with radial laser incision, balloon dilatation and
immediate MMC application (1 mg/ml) during 3 min. The
outcome of this case series showed a statistically signiWcant
diVerence in intervention-free interval in favour of the non-
MMC group. Fifty-Wve percent of the MMC group needed
more than one procedure.
Side eVects in animal studies
Garret et al. [45] examined the inXuence of MMC on vocal
fold healing after micro-Xap excision in a prospective con-
trolled canine model. They treated the excision site with
MMC (0.4 mg/ml) for 3 min. The contralateral vocal folds
were wounded, but not treated with MMC. After 4 weeks, 3
of the 6 dogs showed a persistent concavity in the vocal
fold at the MMC treated excision site. This resulted in a
negative eVect on the vibratory pattern of the treated vocal
folds when compared with the opposite side.
Iniguez-Cuadra et al. [48] performed a prospective, ran-
domized, double-blind, controlled study. They induced
inXammation by circumferential resection and end-to-end
anastomosis of a tracheal annulus in 18 rabbits. Three treat-
ment groups where made: topical saline (isotonic sodium
chloride solution, group A), low dose (0.2 mg/ml, B) and
high dose (0.5 mg/ml, C) topical MMC. All solutions were
applied during 5 min. After 8 weeks, the rabbits were
killed. The eVect of MMC was dose related. In group C,
most rabbits progressed to stenosis with a decrease in air-
way diameter that was signiWcantly larger than in the other
two groups (P < 0.001). The mean percentage of maximum
stenosis in group C was 51%. In groups A and B, it was 18
and 16%, respectively. No signiWcant diVerences in tra-
cheal stenosis between groups A and B were observed.
When compared with the other two groups, the high-dose
MMC group had a signiWcant increase in Wbroproliferative
tissue. The authors conclude that the topical MMC is not
eVective in avoiding tracheal stenosis and may provoke the
opposite eVect when the dose is not carefully selected.
Roh et al. [50] studied the recovering process after diode
laser surgery in the posterior subglottis combined with topi-
cal treatment of a 0.4 mg/ml (group A), 10 mg/ml MMC (B)
or saline solution (C). Either solution was randomly applied
during 5 min in 60 rabbits. Animals were killed at 4 weeks,
and gross and histologic Wndings were compared among
diVerent groups and ten age-matched, non-wound, normal
controls (D). Thirty-two of the 60 (53%) animals died mainly
of acute airway obstruction by necrotic debris, sloughs on or
cartilage collapse of the unhealed posterior subglottis during
early weeks after wounding. This was higher in groups A and
B (67%) than in group C (25%) (P = 0.007). This resulted
from the signiWcant delay of wound healing in groups A and
B when compared with group C (P = 0.012). After 4 weeks,
the surviving 28 rabbits of groups A, B and C showed a sig-
niWcantly decreased cross-sectional area of the scarred lumenEur Arch Otorhinolaryngol (2010) 267:327–334 331
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in comparison to rabbits in group D. There was no statisti-
cally signiWcant diVerence between the treated groups with
regard to cross-sectional area, re-epithelialization or collagen
deposition. Due to the signiWcant risk of acute airway
obstruction from delayed wound healing in rabbits, the
authors suggest that clinicians should pay attention to the
side eVects of MMC, especially when it is used on exposed
cartilage of the airway.
In yet another rabbit model, Roh et al. made two wounds
in 60 rabbits, one in the upper trachea and one in the lower
trachea [51]. The rabbits were divided into three groups.
One group had both wounds as full thickness wounds on
the anterior part of the trachea (A), one group had the two
wounds as partial thickness wounds on the anterior part (B)
and the Wnal group had both wounds as partial thickness
wounds on the circumferential mucosa (C). In each rabbit,
one of the wounds was randomly treated with MMC 1 mg/
ml during 5 min, the other with a saline solution. The inci-
dence of early death was higher in groups A and C than in
group B. This was mainly a result of airway obstruction at
the MMC treated sites. They found comparable cross-sec-
tional area of the lumen between in MMC and saline-
treated wounds, but re-epithelization was signiWcantly
delayed in all MMC wounds. In conclusion, the authors
state that MMC-treated rabbits with tracheal wounds
develop a signiWcant risk of acute airway obstruction.
Discussion
The indications for topical use of MMC are surgical
wounds on areas in the human body where excessive for-
mation of Wbrosis can lead to functional impairment. The
human aerodigestive tract is a good example: obstruction
can be life threatening. By applying a soaked cotton pledget
with MMC solution on the preferred operation site, one can
use it with optimal control in location and time. There is
ample discussion about immediate irrigation after treat-
ment: 33.7% of the researched patients underwent irrigation
of the operation site with a saline solution, which seems to
have a positive eVect on functional outcome as it prevents
excessive Wbrin production.
Several doses of MMC have been used. As it ranged
from 0.1 to 10 mg/ml, one could see that there was no gold
standard. It seems that low doses are ineVective. Hartnick
et al. have used 0.2 mg/ml MMC for 2 min, applied once to
prevent post-intubation stenosis in children in an RCT [39].
After 1 year, their Data Safety and Monitoring Committee
advised to terminate the RCT as interim analysis showed
that there was no diVerence in outcome. The lack of
eYcacy of MMC has also been expressed by other authors
[24,  25,  31,  37], who used concentrations which varied
from 0.4 to 2.0 mg/ml.
In some studies MMC was applied more than once
(Table 1). There seems to be no relation between the number
of MMC applications and side eVects except in the study of
Hueman and Simpson [22] which will be discussed later.
Several side eVects have been reported. Some studies
report adhesions and discharge at the MMC treated side, but
these appeared signiWcantly less frequently than on a similar
wound treated with saline solution [30]. It is a principal
point of discussion whether these eVects can be seen as a
result of the surgery proper and are in that notion not men-
tioned as being a side eVect of topical MMC application.
In our study, an attempt is made to look critically at the
studies with reported side eVects. The following remarks
could be made.
The stenosis and synechia formation of the maxillary
and ethmoidal sinus reported by Anand et al. [36] was of no
statistically signiWcant quantity compared with the non-
MMC treated group.
Hueman and Simpson reported the death of a pediatric
patient suVering from glottic stenosis and recurrent respira-
tory papillomatosis [22]. As mentioned before, this death
occurred in a study for the treatment of laryngeal stenosis
(n = 44) with the use of two diVerent doses of MMC: 0.4
and 10 mg/ml. Both groups showed local toxic eVects of
the MMC. The authors found that the complication rate was
not signiWcantly higher in the high-dose group. They stated
that the unfortunate death was a result of a complex of com-
plications. MMC was used in a 10 mg/ml concentration and
the concentration was increased after four ineVective treat-
ments (with 0.4 mg/ml) without complications. Their study
shows that excessive Wbrin formation can lead to serious
laryngeal obstruction. However, Wbrin does not necessarily
develop due to the use of MMC.
Roh and Yoon evaluated the eVectiveness of topical
MMC in preventing anterior glottic stenosis after transoral
microresection of glottic lesions involving the anterior
commissure [33]. Postoperatively, Wve patients (31%)
developed acceptably small webs in the anterior glottis.
SigniWcant local side eVects or atrophy of the vocal folds
owing to MMC were not found. It is not sure whether the
MMC induced the web, or prevented the formation of a
larger web: they conclude that topical MMC may be useful
in preventing anterior glottic stenosis after surgery in the
anterior commissure [33].
Noureai et al. compared the results of treating acute
post-intubation stenotic airway lesions with the results of
treating mature lesions and to assess whether early inter-
vention improves the outcome [27]. Patients with airway
lesions presenting within weeks of intubation were treated
with intralesional steroids, laser reduction, and balloon
dilatation. Patients with mature airway lesions were ini-
tially treated with laser, balloon dilatation, and topical
MMC. The authors state that patients treated for acute332 Eur Arch Otorhinolaryngol (2010) 267:327–334
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injury required signiWcantly fewer interventions. Their
conclusion, that early treatment of acute Wbro inXammatory
airway lesions has the potential to favorably modify the
natural history of post-intubation tracheal injury, is not
related to beneWcial or adverse eVects of MMC.
Agrawal and Morrison reported a patient with poten-
tially MMC related laryngeal carcinoma in a non-smoking
adult [11]. The chance for this patient of developing laryn-
geal cancer is around 8.8 per 100,000 [53]. This patient,
however, had a long medical history of chronic laryngitis,
with previous removal of a laryngeal polyp and keratosis of
the vocal fold excised. He appeared with anterior webbing.
The authors repeatedly treated this webbing of his anterior
commissure with laser, with or without application of
MMC. As between 16 and 23% patients with keratotic
vocal folds with atypia will subsequently develop a carci-
noma [54], the supposed MMC related carcinoma in this
particular case cannot be attributed to the use of MMC.
Clinical studies with a long follow-up are lacking. As
seen in Table 1, the longest mean follow-up period is
75.5 months. Here, six patients treated with MMC were fol-
lowed [29]. A study to observe the long-term eVects of the
use of MMC is needed, an opinion that has been expressed
by other authors as well [29, 42].
Some of the investigated animal studies do report some
side eVects of the MMC. These are conXicting with the
results of the human studies.
Garret et al. found a decrease in healing response with a
negative consequence on the vocal fold vibratory pattern in
dogs after vocal fold surgery and treatment with MMC
[45]. This Wnding is in contrast with the results of Roh and
Yoon who found no inXuence on the vocal cord quality
after treatment with MMC in humans [33]. However, the
number of animals in Garrett’s study (6 dogs) might be too
small to draw conclusions.
All three studies on rabbits that were analyzed report that
rabbits in the groups treated with MMC died earlier in com-
parison with control groups [48, 50, 51]. This is in contrast
with the fact that all three studies report no signiWcant air-
way reduction in the MMC groups compared with the
saline-treated groups. Two studies reported increase in
inXammation, [50,  51] and one does not [48]. This last
study describes 18 rabbits in three groups, which, again,
might be too small to draw conclusions. Roh’s studies [50,
51] describe a suYcient amount of animals. However, no
information on Wnal wound healing is reported. Only exces-
sive Wbrin production leading to acute airway obstruction
(which, of course, can be endoscopically removed) and
delayed wound healing on exposed cartilage are mentioned.
It is remarkable that the use of MMC causes acute airway
obstruction where the purpose of its use is to reduce the
forming of Wbrosis. This obstruction can be a result of the
early reaction. The severity of cicatricial stenosis (which
can be seen as a late onset reaction) is not inXuenced by the
use of MMC in their animal studies.
Translation of the results on animals to the human body
is disputable, as the structure of the human vocal fold is
diVerent compared with animals. Therefore, the results of
animal studies cannot be directly applied to humans. It can
only give a direction for further research.
Conclusion
As can be concluded from the results, no systemic side
eVects appeared during the topical use of MMC at diVerent
sites in the aerodigestive tract. The eVects that did occur
can be considered as a result of debris that formed after the
procedure. Concerning the eVectiveness of MMC, no rela-
tion could be made with dose, number of applications or
application time. Therefore, no advice can be given.
Unwanted sequelae developed in 19 patients with 519
patients remaining without any side eVects. Only 3.53% of the
investigated human population developed a side eVect from
the topical use of MMC. No side eVects arose in studies where
the application site was irrigated with saline afterwards appli-
cation. In our opinion, these Wndings are no contraindication
for the topical use of MMC in the aerodigestive tract.
There have been reports that high-dose MMC application
on denuded cartilage or traumatized mucosa can lead to tem-
porarily airway obstruction because of Wbrin excess. This
excess of Wbrin can eVectively be removed endoscopically.
Only one case was described where laryngeal carcinoma
theoretically might be attributed to the use of MMC. This
potential development of laryngeal carcinoma after the use
of MMC in the larynx implies that long follow-up is impera-
tive. These Wndings should lead to precautions as in strict
monitoring in the short-term and to a long-term follow-up.
In summary, topical application of MMC on a wound
with consecutive irrigation with saline can be performed
safely to prevent scar formation in circular structures of the
upper aerodigestive tract. Long-term yearly control of the
application site seems advisable.
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